Thank you, Mr. Chair.
I'm interested in how each of your respective systems deals with the issue of high costs of specialty drugs for rare diseases. It's those kind of drugs that sometimes cost tens of thousands of dollars or a hundred thousand dollars a year. Has your system been able to provide those drugs to the patients who need them?
I'll start with you, Ms. Wallström.